RxDoctor Payments Data

Michael Monaco, MD

Internal Medicine · Overland Park, KSNPI 1942263215

Payments from drug & device makers

$1,193in general payments, 2019–2025

Across 52 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$267
  • Esperion Therapeutics, Inc.$203
  • AbbVie$180
  • Phathom Pharmaceuticals, Inc.$79
  • AstraZeneca$76
  • Lilly USA, LLC$74
  • plus $313 from 11 others

What the payments were for

  • Food & beverage$1,193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193 in reported general payments places this provider in the 75th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$54,852
Medicare patients
140
Services billed
10,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$32,870
EliquisApixaban48$31,980
RybelsusSemaglutide24$26,101
OzempicSemaglutide12$16,179
MyrbetriqMirabegron17$12,217
JanumetSitagliptin Phos/Metformin Hcl14$9,821
Xigduo XrDapaglifloz Propaned/Metformin16$9,338
Rosuvastatin Calcium277$4,493
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$4,426
Butorphanol Tartrate14$3,451
Nebivolol Hcl48$2,820
SynthroidLevothyroxine Sodium36$2,599
Levothyroxine Sodium195$2,051
Olmesartan Medoxomil93$1,674
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide28$1,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$267$42,27936 claims
Lilly USA, LLCMounjaro$74$32,87028 claims
AbbVieSynthroid$180$2,59936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →